Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

243
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
243
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

278
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
278
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

212
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
212
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

205
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
205
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

248
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
248
EPS and iPS Cells in Disease Research01:21

EPS and iPS Cells in Disease Research

2.9K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
2.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Response to: "Letter to the Editor Regarding 'Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis'".

Dermatology and therapy·2026
Same author

Rethinking Head and Neck Atopic Dermatitis: Pathogenic Axes and Emerging Therapeutic Directions.

American journal of clinical dermatology·2026
Same author

Generalized Pustular Psoriasis in Portugal: Expert Perspectives on Patient Journey, Diagnosis, Therapeutic Goals, and Healthcare Optimization.

Acta medica portuguesa·2026
Same author

Global Healthcare Study on Psoriasis (GHSP): cohort profile and first findings.

BMJ open·2026
Same author

Treatment-associated phenotype switching between psoriasis and atopic dermatitis.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

Complete clearance of high-impact sites with risankizumab in patients with psoriasis: a 2-year real-world retrospective multicenter cohort study.

The Journal of dermatological treatment·2026
Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)·2023
See all related articles

Related Experiment Video

Updated: Sep 20, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.1K

Bimekizumab for psoriasis.

Maria Alexandra Rodrigues1, Egídio Freitas1, Tiago Torres1,2,3

  • 1Department of Dermatology, Centro Hospitalar do Porto, Porto, Portugal.

Drugs of Today (Barcelona, Spain : 1998)
|June 7, 2022
PubMed
Summary
This summary is machine-generated.

Bimekizumab, a dual inhibitor of interleukin-17A and 17F, offers a highly effective treatment for moderate to severe plaque psoriasis. Clinical trials demonstrate its rapid, sustained efficacy and superior performance compared to other biologics.

Keywords:
Anti-interleukin-17 (IL-17) agentsAutoimmune diseasesBimekizumabDermatological disordersMonoclonal antibodiesPsoriasis

More Related Videos

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

506
Development of an Economical DNA Delivery System by "Acufection" and its Application to Skin Research
09:42

Development of an Economical DNA Delivery System by "Acufection" and its Application to Skin Research

Published on: April 19, 2017

7.5K

Related Experiment Videos

Last Updated: Sep 20, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.1K
Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

506
Development of an Economical DNA Delivery System by "Acufection" and its Application to Skin Research
09:42

Development of an Economical DNA Delivery System by "Acufection" and its Application to Skin Research

Published on: April 19, 2017

7.5K

Area of Science:

  • Immunology
  • Dermatology
  • Pharmacology

Background:

  • Psoriasis is a chronic inflammatory skin disease affecting 1-3% of Western populations.
  • Advances in understanding the interleukin-23 (IL-23)/T-helper 17 (Th17) axis have led to targeted biologic therapies.
  • Some patients exhibit inadequate response or loss of response to existing psoriasis treatments.

Purpose of the Study:

  • To evaluate the efficacy and safety of bimekizumab, a dual inhibitor of IL-17A and IL-17F, for moderate to severe plaque psoriasis.
  • To compare bimekizumab's performance against established biologic therapies in active-comparator trials.

Main Methods:

  • Bimekizumab is a humanized monoclonal IgG1 antibody targeting IL-17A and IL-17F.
  • Clinical studies assessed bimekizumab's efficacy, onset, and duration of response in psoriasis patients.
  • Active-comparator trials (BE SURE, BE VIVID, BE RADIANT) compared bimekizumab to adalimumab, ustekinumab, and secukinumab.

Main Results:

  • Bimekizumab demonstrated high and sustained efficacy in psoriasis patients, with rapid onset of response up to 60 weeks.
  • Bimekizumab showed superiority over adalimumab, ustekinumab, and secukinumab in head-to-head trials.
  • The drug exhibited a consistent safety profile and high tolerability, with mucosal candidiasis as the most common adverse event.

Conclusions:

  • Dual inhibition of IL-17A and IL-17F by bimekizumab represents a highly effective treatment strategy for psoriasis.
  • Bimekizumab is approved for moderate to severe plaque psoriasis in Europe, Canada, and Japan, offering a new therapeutic option.